121 results about "Levamisole" patented technology

The invention discloses a special diluent for swine mycoplasmal pneumonia vaccines. The special diluent mainly contains a recombinant P97R1 protein immunostimulating complex (ISCOM-P97R1); and in addition, the special diluent also possibly contains other water-based adjuvants comprising levomisole, astragalus polysaccharide or/and carbomer. 1 ml of diluent solution contains 0.1-1 mg of QuilA, 0.02-0.2 mg of cholesterol, 0.02-0.2 mg of phosphatidylcholine and 0.4-4 mg of P97R1 antigen; and in addition, 1 ml of diluent solution also possibly contains 2-20 mg of levomisole, 20-100 mg of astragalus polysaccharide or/and 3-10 mg of carbomer and a phosphate buffer solution for the rest. The diluent is specially used for dissolving or diluting the swine mycoplasmal pneumonia vaccines comprising a live vaccine and an inactivated vaccine, has the double effects of complementing vaccine antigen protection spectrums and improving the vaccine cell and humoral immunostimulation capability, can remarkably improve the toxic attack protection efficacy of the vaccines, and also has the advantages of being simple and convenient to operate, good in syringeability and free from remarkable toxic side reaction due to the adoption of a hydrosolvent system at the same time.

The invention relates to a composite immunity intensifier for groupers, which comprises the following components according to weight percentage: 30 to 40 percent of Beta-dextran, 10 to 20 percent of A3 Alpha peptidoglycan, 10 to 20 percent of vitamin C-2- polyphosphate ester, 10 to 20 percent of levomisole, 5 to 10 percent of ginsenoside and 5 to 10 percent of vitamin E. The invention has the advantages that: firstly, the composite immunity intensifier effectively overcomes the problem that the body reverse feedback of the groupers is restrained and can be used in the whole culturing period of the groupers; secondly, the composite immunity intensifier as a feed additive is used in the compound feed of the groupers and only has 0.1 to 0.2 percent of addition amount; thirdly, the body immunity of the groupers is intensified obviously and the survival rate is improved; fourthly, the composite immunity intensifier has no bad effect on the palatability of feed; and fifthly, the raw material used by the composite immunity intensifier has stable source, low price and simple production process.

The invention relates to a compound immunoenhancement agent and an application thereof on preparing a vaccine for birds. The compound immunoenhancement agent contains 5ng-10mg/mL of poly IC, 10ng-10mg/mL of muramyl dipeptide, 10ng-5mg/mL of levamisole, 10ng-5mg/mL of resiquimod and 10ng-5mg/mL of imiquimod. After the immunoenhancement agent and H5 hypotype bird flu inactivated vaccine are mixed together, antibody can be produced one week earlier, and the antibody titer is improved above 1.8log2. After chicken are immunized through H5 hypotype bird flu inactivated vaccine, H9 hypotype bird flu vaccine or infectious bronchitis vaccine which contains the compound vaccine immunoenhancement agent, the window phases of the antibody production are shortened, the antibody titer of the vaccine is improved, the immunization duration is prolonged, and the probability of infection disease is reduced.

The invention relates to a compound immunopotentiator for golden pomfrets, which comprises following ingredients by weight percentages: 20 to 30 percent of beta-dextran, 10 to 20 percent of levamisol, 10 to 20 percent of lentinan, 10 to 15 percent of vitamin A, 10 to 20 percent of vitamin E and 10 to 15 percent of selenium methionine. The invention effectively overcomes the problem of reverse feedback inhibination of golden pomfret organisms, can be used in a complete culture period of the golden pomfrets, is used as a feed additive to be added in golden pomfret feed by only 0.1 percent to 0.2 percent, obviously enhances the organism immunity of the golden pomfrets, improves the live rate, and has no influence on the palatability of the feed; and raw materials used in the compound immunopotentiator have stable resources, low cost and simple production technology.

This invention relates to antihelminthic pharmaceutical combinations comprising iodinated aromatic compounds, such as disophenol or nitroxynil, with other pharmaceutical active ingredients targeting the treatment of animals. More specifically, this invention concerns pharmaceutical compositions comprising disophenol or nitroxynil with at least one other pharmaceutical antihelminthic active ingredient, selected from among benzimidazoles, thiabendazole, levamisole or tetramisole salts, avermectins or milbemycins and, even more preferably, levamisole salts selected from between levamisole chloride or phosphate.

This invention also relates to medications and a method for treating animals comprising such antihelminthic medications.

The invention discloses a compound panax ginseng saponin and levamisole nano emulsion adjuvant. The adjuvant has the particle diameter of 1-100 nm and comprises panax ginseng saponin, levamisole, a surface active agent, a cosurfactant, oil and distilled water. The product is transparent faint yellow liquid in appearance, and the particle parameter is smaller than 100 nm; the viscosity is lower, and the viscosity requirement of emulsion as a vaccine adjuvant is met; the stability is higher, and the product can be preserved at room temperature or 4 DEG C for a long time; the special emulsification is not needed during seedling preparation, the requirement to equipment is low, and the quality of the product is easy to control. Egg white albumin (OVA) as mode antigen indicates that the compound panax ginseng saponin and levamisole nano emulsion adjuvant can induce better immune reaction than an aluminum adjuvant in a certain dosage, generate higher antibody titer, reduce the dosage of theadjuvant or the antigen, simulate Th1 and Th2 reaction, reinforce the body fluid and cell immunization of an organism and play a role of complete immune protection.

The invention provides a mosaic gene, which comprises a gene for coding tubercle bacillus protein Ag85a and a gene which is mosaiced at a Kpn I recognition sequence at sites 245-250 and/or an Acc I recognition sequence at sites 430-435 of Ag85a gene for coding the tubercle bacillus protein Ag85b. The invention provides a mosaic gene-containing mosaic tubercle bacillus gene vaccine, wherein the Ag85a gene is connected to a eukaryotic expression vector. The invention also provides a preparation method of the mosaic tubercle bacillus gene vaccine. The method comprises the following steps of: performing PCR (Polymerase Chain Reaction) amplification on an Ag85b gene segment; inserting the amplified Ag85b gene segment into the Ag85b gene-containing eukaryotic expression vector; and connecting by using ligase. The mosaic tubercle bacillus gene vaccine can be used for treating drug-resistant tubercle bacillus infection and can also be used in combination with levamisole serving as an adjuvantto induce stronger anti-tubercular cell immunological response.

The present invention is directed to stabilized compositions comprising at least one macrocyclic lactone, or derivative thereof, in combination with levamisole, and an amino sugar stabilizing agent, optionally an additional antiparasitic agent, and a method for treating or controlling a parasitic infection or infestation in an animal by administering said composition.

The invention discloses a novel disease-resistant additive for adult procambarus clarkii shrimps. The novel disease-resistant additive comprises the following components in parts by weight: 30-80 parts of a plant extraction polysaccharide compound, 20-50 parts of a yeast compound, 5-40 parts of levamisole, and 5-30 parts of sodium alginate, wherein the plant extraction polysaccharide compound comprises 30-40 parts of astragalus polysaccharide, 15-20 parts of bamboo shoot polysaccharide, and 20-25 parts of rice bran polysaccharide; and the yeast compound comprises 20-40 parts of yeast cell walls and 20-30 parts of selenium yeast. According to immunoenhancement components which are screened, not all the components having the best immunoenhancement properties are combined, while through comprehensive consideration of complementary characteristics, synergistic efficacy and immunoenhancement effects of the components, under the combined action of the components and within a specific contentrange, synergistic effects are achieved. The disease-resistant additive disclosed by the invention is added to the feed, so that the disease resistance of the adult shrimps can be obviously improved,the breeding survival rate can be increased, the breeding yield can be increased, and the mortality rate of the adult shrimps can be reduced. The water quality of a pond can be improved to a certainextent, the used raw material sources are stable to supply, and the production technology is simple.

The technology belongs to the technical field of aquiculture disease prevention, in particular to the preparation method of the immune reinforcing agent for cultivating crustacean, and the applicationmethod thereof. The aquiculture composite immune reinforcing agent comprises 2-4 parts of aquiculture extractive or baicalin and 2.5-5 parts of levamisole. The composite immune reinforcing agent caneffectively enhance non-specific immunity for cultivating blue crab, improve the activity of the blood serum phenol oxidase, the superoxide dismutase and the alkalinephosphatase of the blue crab, andimproves the disease resistance of the blue crab to common pathogens such as white spot syndrome virus, vibrio, hematodinium, etc. The composite immune reinforcing agent can be applied to the cultivation of the blue crab by being injected or added into blue crab fresh fish bait and granulated feed for preventing and controlling the disease at the disease peak and reducing the disease rate and themortality rate of the blue crab. The immune reinforcing agent is added into the feed for preventing and controlling the disease of the penaeus vannamei boone and exopalaemon carinicauda.

The invention belongs to the field of veterinary drugs, and discloses a medicine composition used for controlling poultry airsacculitis. The composition is composed of the components of, by weight: 10-20% of aesculetin, 10-20% of deoxycycline, 10-20% of colistine sulfate, 2-5% of levamisole, 10-30% of vitamin C, 0.01-0.015% of dexamethasone, and balance of auxiliary materials. The invention also provides a preparation method of the medicine composition. The medicine composition provided by the invention has high effect against poultry airsacculitis, wherein an effective rate can be higher than 95%. The medicine composition is also advantaged in fast effect. In a first day of medication, a substantial effect can be provided, and the disease can be cured in 4 days. Also, the medicine composition has a wide antimicrobial spectrum. The medicine composition has excellent killing effects against poultry airsacculitis pathogens such as Escherichia coli, mycoplasma, pseudomonas aeruginosa, and the like. The medicine composition can effectively control secondary bacterial infections. Further, the medicine composition provided by the invention is advantaged in simple production method and convenient application. The production method is labor-saving.

The invention discloses a method for quickly screening stichopus japonicus immune enhancers with high throughput, which is characterized by comprising the following steps: firstly determining beta-glucan, peptidoglycan, chitosan, mannan-oligosaccharide, CpG-oligodeoxynucleotide, soy peptide, lactoferrin, levamisole, vitamin C and vitamin E as the screened immune enhancers, then carrying out primary culture for stichopus japonicus coelom cells, detecting four sensitive immune indexes of the immune enhancers on stichopus japonicus by the cultured stichopus japonicus coelom cells, namely effects of phagotrophy rate, superoxide anion content, superoxide dismutase activity and nitric oxide synthase activity, and determining a screening result for the effects of the four indexes according to the immune enhancers. The method can screen the immune enhancers on large scale and in short time, and simultaneously can research the action mechanisms of the various immune enhancers and lay a foundation for the deep study of the immune enhancers.

The invention discloses a vaccine adjuvant and an application thereof in preparation of a Newcastle disease inactivating vaccine, and belongs to the field of the preparation of a Newcastle disease inactivating vaccine. The invention discloses a method for preparing the Newcastle disease inactivating vaccine by virtue of the vaccine adjuvant. The method comprises the following steps: (1) proliferating Newcastle disease viruses, collecting a virus solution and inactivating the virus solution; (2) adding a levomisole mother liquid to the inactivated virus mother liquid and uniformly mixing so as to obtain an aqueous phase solution; (3) adding a surfactant to the aqueous phase solution and uniformly mixing; and (4) adding white oil and emulsifying so as to obtain the Newcastle disease inactivating vaccine. The Newcastle disease inactivating vaccine prepared by the method disclosed by the invention is good in safety, and the vaccine can stimulate a body to generate relatively strong cellular immunity and humoral immunity and prolong the immune protection period thereof.

The invention discloses a compound preparation for treating cecal granuloma and a preparation method thereof. The compound preparation comprises chloroquine phosphate, diiodohydroxyquinoline, chlorogenic acid, liquiritin, cistanoside, ursolic acid, polysavone, levamisole, albendazole, okra powder, lactein, vitamin B1, lactalbumin and arginine. The compound preparation can effectively expand intestinal tubes, prevent intestinal obstruction, prevent mesentery and intestinal wall inflammatory infiltration and edema, prevent intestinal wall fibrosis, adjust body metabolism, improve immunity, reduce drug side effects and treat cecal granuloma and has a wide application prospect.

The invention discloses an immunopotentiator for an adult portunus trituberculatus and an application thereof. The immunopotentiator is characterized by being prepared by evenly mixing the following raw materials in parts by weight: 5-10 parts of levamisole, 15-20 parts of astaxanthin, 10-20 parts of hypoxanthine nucleotide, 20-30 parts of beta-1,3-glucan, and 30-40 parts of seaweed polysaccharides. The mass percentage content of the immunopotentiator in a feeding feed is 0.06-0.08%. The immunopotentiator has the advantages that: the addition amount of the immunopotentiator in the feed is only 0.06-0.08%, thus the immunity and the disease resistance of the adult portunus trituberculatus are significantly improved, so as to improve the survival rate of breeding portunus trituberculatus, wherein the survival rate can be increased by 26% or more, and the immune protection rate can reach 59% or more; and the immunopotentiator has no toxic or side effect, no residue and no drug resistance, also has no adverse effect on the feed palatability, has less addition amount, and can significantly improve the efficacy of the immunity and the disease resistance of the adult portunus trituberculatus.

A slow-releasing compound immunopotentiator for chicken is proportionally prepared from the medicinal components including astragalus polyose, epimedium polyose, levamisole, VE and sodium selenite, and the matrix components including epoxy resin, ethyldiamine, dibutyl phthalate and talc powder. Its preparing process is also disclosed.

The invention discloses an antibacterial and antiviral traditional Chinese medicine preparation for poultry, which is characterized by being composed of the following components: 110-130 parts of gypsum, 28-32 parts of radix rehmanniae, 59-61 parts of buffalo horn, 19-21 parts of coptis, 28-32 parts of Gardenia, 19-21 parts of tree peony bark, 24-26 parts of radix scutellariae, 24-26 parts of red paeonia, 24-26 parts of figwort, 28-32 parts of rhizoma anemarrhenae, 28-32 parts of forsythia, 24-26 parts of balloonflower, 14-16 parts of licorice, 24-26 parts of lophatherum, 10-20 parts of goldenrod and 5-15 parts of levamisole. The traditional Chinese medicine preparation is nontoxic, harmless and pollution-free, can effectively improve the antibacterial and antiviral capabilities of the poultry, can effectively replace antiviral Western medicines so as to provide pollution-free livestock and poultry products for the society, is lower in cost and is convenient for industrial popularization.

Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine. A veterinarian formulation comprising of organics salts of levamisole, more specifically to the disophenolat salt of levamisole and the nitroxynil-salt of levamisole with avermectines and milbemycines and its use in treatment of helminthiasis in mammals, in particular in bovines, swines, caprines, equines, ovines, canines and felines.